Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aditxt Inc (ADTX)

Aditxt Inc (ADTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 100
  • Shares Outstanding, K 57
  • Annual Sales, $ 130 K
  • Annual Income, $ -34,450 K
  • EBIT $ -28 M
  • EBITDA $ -24 M
  • 60-Month Beta 1.60
  • Price/Sales 0.71
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5100 +16.56%
on 05/08/25
2.7600 -36.23%
on 05/05/25
-0.7400 (-29.60%)
since 04/17/25
3-Month
1.5100 +16.56%
on 05/08/25
33.2500 -94.71%
on 02/21/25
-27.9400 (-94.07%)
since 02/20/25
52-Week
1.5100 +16.56%
on 05/08/25
27,200.0000 -99.99%
on 07/17/24
-20,898.2400 (-99.99%)
since 05/20/24

Most Recent Stories

More News
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

APLIF : 0.0112 (-44.00%)
APLI.TO : 0.0200 (-33.33%)
ADTX : 1.7600 (+0.57%)
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

APLIF : 0.0112 (-44.00%)
APLI.TO : 0.0200 (-33.33%)
ADTX : 1.7600 (+0.57%)
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

APLIF : 0.0112 (-44.00%)
APLI.TO : 0.0200 (-33.33%)
ADTX : 1.7600 (+0.57%)
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

SLDB : 2.88 (-0.69%)
SLRN : 2.26 (+1.35%)
ESLA : 0.9782 (-0.23%)
CADL : 5.82 (+2.11%)
ADTX : 1.7600 (+0.57%)
Microcap Biotech Aditxt Rallies Retail Interest Ahead Of CEO’s Fireside Chat: What’s On Investors’ Radar?

The event will cover Adimune, Inc., which focuses on autoimmunity treatments, and subsidiary Pearsanta's planned IPO in 2025.

VXF : 185.54 (-0.41%)
ADTX : 1.7600 (+0.57%)
Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome

Aditxt®, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that modulate and monitor the immune system, today announces that...

ADTX : 1.7600 (+0.57%)
Aditxt (NASDAQ: ADTX) Closes on $1.9M Registered Direct Offering

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced that it has closed on its previously announced registered...

ADTX : 1.7600 (+0.57%)
Aditxt Announces Closing of $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced...

ADTX : 1.7600 (+0.57%)
Aditxt Inc. (NASDAQ: ADTX) Registered Direct Offering Expected to Total $1.9M

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has entered into a definitive agreement. The company...

ADTX : 1.7600 (+0.57%)
Aditxt (NASDAQ: ADTX) Inks Agreement for 50% Ownership of Global Response Aid

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, has signed an asset purchase agreement with Cellvera Ltd. According...

ADTX : 1.7600 (+0.57%)

Business Summary

Aditx Therapeutics Inc. is a life sciences company. It engages in developing biotechnologies specifically focused on health of the immune system through immune monitoring and reprogramming. Aditx Therapeutics Inc. is based in LOMA LINDA, CA.

See More

Key Turning Points

3rd Resistance Point 1.8933
2nd Resistance Point 1.8367
1st Resistance Point 1.7933
Last Price 1.7600
1st Support Level 1.6933
2nd Support Level 1.6367
3rd Support Level 1.5933

See More

52-Week High 27,200.0000
Fibonacci 61.8% 16,810.1750
Fibonacci 50% 13,600.7540
Fibonacci 38.2% 10,391.3330
Last Price 1.7600
52-Week Low 1.5100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar